Envestnet Asset Management Inc. decreased its position in shares of HCA Healthcare Inc (NYSE:HCA) by 50.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,496 shares of the company’s stock after selling 1,525 shares during the quarter. Envestnet Asset Management Inc.’s holdings in HCA Healthcare were worth $208,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Panagora Asset Management Inc. boosted its stake in shares of HCA Healthcare by 44.0% during the third quarter. Panagora Asset Management Inc. now owns 36,733 shares of the company’s stock worth $5,110,000 after buying an additional 11,216 shares during the period. Millennium Management LLC boosted its stake in shares of HCA Healthcare by 32.3% during the second quarter. Millennium Management LLC now owns 1,698,536 shares of the company’s stock worth $174,270,000 after buying an additional 414,877 shares during the period. WINTON GROUP Ltd boosted its stake in shares of HCA Healthcare by 3,350.7% during the third quarter. WINTON GROUP Ltd now owns 205,078 shares of the company’s stock worth $28,530,000 after buying an additional 199,135 shares during the period. C WorldWide Group Holding A S boosted its stake in shares of HCA Healthcare by 16.6% during the third quarter. C WorldWide Group Holding A S now owns 92,727 shares of the company’s stock worth $12,900,000 after buying an additional 13,192 shares during the period. Finally, Aperio Group LLC boosted its stake in shares of HCA Healthcare by 7.5% during the third quarter. Aperio Group LLC now owns 224,614 shares of the company’s stock worth $31,248,000 after buying an additional 15,680 shares during the period. 69.74% of the stock is currently owned by institutional investors.
In related news, insider Michael S. Cuffe sold 5,196 shares of HCA Healthcare stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $136.52, for a total transaction of $709,357.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jane D. Englebright sold 5,081 shares of HCA Healthcare stock in a transaction on Friday, November 9th. The shares were sold at an average price of $141.90, for a total transaction of $720,993.90. Following the transaction, the senior vice president now owns 16,504 shares in the company, valued at approximately $2,341,917.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,763 shares of company stock worth $2,346,147. 2.80% of the stock is owned by company insiders.
HCA stock opened at $134.54 on Friday. The company has a market capitalization of $45.54 billion, a price-to-earnings ratio of 20.42, a PEG ratio of 1.07 and a beta of 0.69. HCA Healthcare Inc has a one year low of $90.06 and a one year high of $147.42.
HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, October 30th. The company reported $2.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.93 by $0.23. The firm had revenue of $11.45 billion during the quarter, compared to analysts’ expectations of $11.29 billion. HCA Healthcare had a net margin of 6.82% and a negative return on equity of 73.71%. HCA Healthcare’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.13 EPS. As a group, equities analysts anticipate that HCA Healthcare Inc will post 9.35 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Monday, December 3rd were issued a $0.35 dividend. The ex-dividend date of this dividend was Friday, November 30th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.04%. HCA Healthcare’s dividend payout ratio (DPR) is presently 21.24%.
A number of equities research analysts recently commented on HCA shares. Zacks Investment Research downgraded shares of HCA Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, December 11th. Credit Suisse Group raised their price objective on shares of HCA Healthcare from $156.00 to $165.00 and gave the company an “outperform” rating in a research report on Thursday, November 1st. Stephens started coverage on shares of HCA Healthcare in a research report on Monday, January 14th. They issued an “overweight” rating and a $143.00 price objective for the company. Finally, Argus raised their price objective on shares of HCA Healthcare from $150.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, November 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $143.14.
WARNING: This piece was posted by Fairfield Current and is the property of of Fairfield Current. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/01/19/hca-healthcare-inc-hca-shares-sold-by-envestnet-asset-management-inc.html.
About HCA Healthcare
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
See Also: How accurate is the Rule of 72?
Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.